Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1α expression, resulting in reduced angiogenesis

Oncogene

Volumn 25, Issue 17, 2006, Pages 2509-2519

  Yin, M B ^a   Li, Z R ^a   Toth K ^a   Cao, S ^a   Durrani, F A ^a   Hapke, G ^a   Bhattacharya, A ^a   Azrak, R G ^a   Frank, C ^a   Rustum, Y M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; COX 2; HIF 1 ; iNOS; Irinotecan; MSC

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CASPASE; CELL CYCLE PROTEIN 6; CHECKPOINT KINASE 2; CYCLOOXYGENASE 2; DNA TOPOISOMERASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; IRINOTECAN; METHYLSELENOCYSTEINE; MINICHROMOSOME MAINTENANCE PROTEIN 2; MUTANT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTAGLANDIN E2; PROTEIN P53; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME DEGRADATION; FEMALE; GENE EXPRESSION; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; CYSTEINE; DOWN-REGULATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; ORGANOSELENIUM COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA;

EID: 33645805420     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209073     Document Type: Article

References (57)

1. Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS, Kim YS. (2005). Life Sci 76: 2315-2328.
2. Apostolou S, Klein JO, Mitsuuchi Y, Shetler JN, Poulikakos PI, Jhanwar SC et al. (2004). Oncogene 23: 5032-5040.
3. Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, Yin MB et al. (2004). Clin Cancer Res 10: 1121-1129.
4. Bhattacharya A, Toth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L et al. (2004). Clin Cancer Res 10: 8005-8017.
5. Bing RJ, Miyataka M, Rich KA, Hanson N, Wang X, Slosser HD et al. (2001). Clin Cancer Res 7: 3385-3392.
6. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. (2003). FASEB J 17: 1159-1161.
7. Cao S, Durrani FA, Rustum YM. (2004). Clin Cancer Res 10: 2561-2569.
8. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC et al. (2004). Proc Natl Acad Sci USA 101: 591-596.
9. Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. (2002). J Pathol 198: 435-441.
10. Chen Y, Yang L, Lee TJ. (2000). Biochem Pharmacol 59: 1445-1457.
11. Cherukuri DP, Goulet AC, Inoue H, Nelson MA. (2005). Cancer Biol Ther 4: 175-180.
12. Chun KS, Cha HH, Shin JW, Na HK, Park KK, Chung WY et al. (2004). Carcinogenesis 25: 445-454.
13. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A et al. (2001). Gastroenterology 121: 1339-1347.
14. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N et al. (2004). Clin Cancer Res 10: 2694-2704.
15. Cianchi F, Cortesini C, Fantappie O, Messerini L, Schiavone N, Vannacci A et al. (2003). Am J Pathol 162: 793-801.
16. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC. (1997). J Histochem Cytochem 45: 923-934.
17. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. (2003). J Biol Chem 278: 18008-18014.
18. Dimmeler S, Zeiher AM. (2000). Circ Res 86: 4-5.
19. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N et al. (1998). Cell 94: 715-725.
20. Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A. (2002). Biochem Biophys Res Commun 299: 517-524.
21. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA et al. (1998). J Nat Cancer Inst 90: 587-595.
22. Ganther HE. (1999). Carcinogenesis 20: 1657-1666.
23. Giaccia AJ, Shieh J, Cholon A, Brown JM. (1991). Mutat Res 263: 69-75.
24. Guo B, Cao S, Toth K, Azrak RG, Rustum YM. (2000). Clin Cancer Res 6: 718-724.
25. Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE et al. (2004). Cancer Res 64: 6849-6853.
26. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. (2003). Trends Mol Med 9: 73-78.
27. Ip C, Zhu Z, Thompson HJ, Lisk D, Ganther HE. (1999). Anticancer Res 19: 2875-2880.
28. Jiang B, Xu S, Hou X, Pimentel DR, Brecher P, Cohen RA. (2004). J Biol Chem 279: 1323-1329.
29. Jiang C, Jiang W, Ip C, Ganther H, Lu J. (1999). Mol Carcinog 26: 213-225.
30. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ et al. (1999). Nat Med 5: 1418-1423.
31. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. (2003). FASEB J 17: 2115-2117.
32. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM et al. (2002). Cancer Res 62: 6850-6856.
33. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. (2002). Science 295: 858-861.
34. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E et al. (2001). J Biol Chem 276: 18563-18569.
35. Lu J. (2001). Adv Exp Med Biol 492: 131-145.
36. Lu J, Jiang C. (2001). Nutr Cancer 40: 64-73.
37. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al. (2000). Cancer Res 60: 1306-1311.
38. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ et al. (1997). Proc Natl Acad Sci USA 94: 8104-8109.
39. Medina D, Morrison DG. (1988). Pathol Immunopathol Res 7: 187-199.
40. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. (2005). Int J Cancer 113: 490-498.
41. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. (2002). Proc Natl Acad Sci USA 99: 12483-12488.
42. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T et al. (2003). J Biol Chem 278: 37937-37947.
43. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE et al. (1993). EMBO J 12: 3679-3684.
44. Park SW, Lee SG, Song SH, Heo DS, Park BJ, Lee DW et al. (2003). Int J Cancer 107: 729-738.
45. Pichiule P, Chavez JC, LaManna JC. (2004). J Biol Chem 279: 12171-12180.
46. Rajnakova A, Moochhala S, Goh PM, Ngoi S. (2001). Cancer Lett 172: 177-185.
47. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA et al. (2004). Cancer Res 64: 6845-6848.
48. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR. (2002). Cancer Epidemiol Biomarkers Prev 11: 1285-1291.
49. Schwartz DC, Cantor CR. (1984). Cell 37: 67-75.
50. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK et al. (2001). Mutation Res 480/481: 243-268.
51. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. (1998). Cell 93: 705-716.
52. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. (2004). Cancer Res 64: 2030-2038.
53. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. (1998). Carcinogenesis 19: 711-721.
54. Yin MB, Li ZR, Cao S, Durrani FA, Azrak RG, Frank C et al. (2004). Mol Pharmacol 66: 153-160.
55. Zhou N, Xiao H, Li TK, Nur-E-Kamal A, Liu LF. (2003). J Biol Chem 278: 29532-29537.
56. Ziehe M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ et al. (1997). J Clin Invest 99: 2625-2634.
57. Ziche M, Morbidelli L, Masini E, Granger H, Geppetti P, Ledda F. (1993). Biochem Biophys Res Commun 192: 1198-1203.